Who We Are
Calivanta BioPharma is an AI-powered biotech company building proprietary drug discovery platforms and partnering with pharmaceutical organizations, emerging biotech firms, and leading academic medical centers. Our model combines internal pipeline development through computational protein design and molecular simulation with multi-year platform co-development agreements — delivering real therapeutic innovation through AI-driven discovery and precision medicine.
Since our founding, we have established active partnerships with 12+ pharmaceutical and biotech organizations across three continents. Our current R&D portfolio includes five proprietary platforms at various stages of development and commercialization:
CaliOmics — Our flagship multi-omics integration engine, combining deep learning with molecular dynamics simulation to identify and validate therapeutic targets. Licensed to multiple pharma partners under multi-year agreements. Applied across oncology, immunology, and rare disease — accelerating hit-to-lead timelines versus conventional methods.
TherAlign — Precision oncology biomarker discovery platform using machine learning to identify predictive signatures across solid tumors and hematological malignancies. Several biomarker panels in co-development with pharma partners, supporting precision medicine and companion diagnostic programs.
ImmunoScope — Comprehensive immune profiling platform for IO drug development, analyzing TCR repertoires, tumor microenvironment transcriptomics, and circulating immune cell dynamics. Deployed with major pharma partners developing next-gen checkpoint inhibitors and CAR-T therapies.
PathwayPredict — Systems pharmacology platform for MOA prediction and off-target liability assessment. In early access with leading biopharma companies. Deconvolutes drug mechanisms and predicts safety liabilities with strong accuracy in retrospective validation studies.
ClinicalConnect — Real-world evidence platform combining EHR, claims, and registry data to optimize clinical trial design, patient stratification, and regulatory submission packages. Supporting FDA and EMA strategies for partners across US and European markets.
Based in Switzerland with operations in Europe and North America, our team includes computational biologists, AI/ML researchers, medicinal chemists, and regulatory strategists. Revenue comes from proprietary pipeline development, platform licensing, partnership milestone payments, and success-based fees tied to therapeutic validation.